Arvinas (ARVN) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Strategic overview and pipeline focus

• Transitioned focus from initial product launch to advancing four clinical pipeline programs, with key data readouts expected over the next nine months.

• Programs span oncology and neurology, with no bias toward either; prioritization will be data-driven as results emerge.

• Cash runway extends into the second half of 2028, supporting advancement of all current clinical programs through key inflection points.

• Capital allocation is focused on efficiency and value creation, with decisions to wholly own or partner assets based on strategic fit and data.

• No set limit on the number of programs to advance; decisions will be guided by excitement and investor interest as data matures.

Program updates and clinical development

• ARV-393 (BCL6 degrader) for hematology will have initial phase I data by year-end, focusing on safety, PK/PD, and T cell lymphoma patients, with broader efficacy data and combination results expected mid-next year.

• LRRK2 degrader in neurodegeneration to present new biomarker data at MDS Congress, showing synaptic and neuroinflammatory biomarker improvements not seen with inhibitors.

• ARV-027, an androgen receptor degrader for Kennedy's disease (SBMA), began phase I this year, targeting the disease's direct cause with strong biological rationale and patient community engagement.

• HPK1 degrader (ARV-6723) has entered the clinic as the first immuno-oncology program, expanding the pipeline's reach.

• VEPPANU, now partnered and launched, brings upfront and milestone payments plus royalties, with commercial progress closely watched.

Scientific rationale and combination strategies

• PROTAC degraders offer advantages over inhibitors by overcoming rapid target resynthesis and enabling durable protein degradation, especially for targets like BCL6.

• Preclinical and early clinical data support monotherapy and combination approaches, with ARV-393 showing synergy with agents like glofitamab and potential for all-oral regimens.

• Combination strategies are designed to deepen and extend responses, with plans to move from late-line monotherapy to earlier-line combinations in both B and T cell lymphomas.

• LRRK2 degrader demonstrates unique biomarker and synaptic endpoint improvements, supporting its differentiation from inhibitors and informing future clinical endpoints.

• PSP program timelines are contingent on regulatory feedback, with endpoints likely to include the PSP Rating Scale and a suite of biomarkers.